Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
31 hedge funds and large institutions have $9.74M invested in Hepion Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 10 closing their positions.
1,111% more call options, than puts
Call options by funds: $678K | Put options by funds: $56K
8% more capital invested
Capital invested by funds: $9M → $9.74M (+$740K)
21% less funds holding
Funds holding: 39 → 31 (-8)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$85.1K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$32K |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$8.84K |
| 5 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$8.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$57K |
| 2 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$56K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$34.3K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$28K |
HEPA Hedge Fund Activity: Q1 2022 in Review
31 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2022, worth a combined $9.74M — up 8.2% from $9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HEPA and 3 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $85.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $57K sold.
- 31 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2022, down from 39 in Q4 2021.
- Funds reported $9.74M of Hepion Pharmaceuticals stock for Q1 2022, up 8.2% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q1 2022 and 10 closed out, a net change of -7 holders.
- The largest Hepion Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $85.1K added.
- The largest Hepion Pharmaceuticals seller in Q1 2022 was Virtu Financial, an estimated $57K sold.
Based on aggregated 13F filings for Q1 2022.